|
California San Francisco Cancer News is an EIN News Service for health professionals. Constantly updated news and information about California Health.
Latest California San Francisco Cancer News
- Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126 24 Nov 2009 06:40 GMT
... currently in Phase II development in pancreatic cancer. CP-4126 is a novel, patented, lipid-conjugated form ... to be critical for gemcitabine entry into tumor cells, whereas CP-4126 enters and kills tumour ... Boulder, Colorado, and has additional offices in San Francisco, CA and London, UK. Clavis Pharma ASA ...
- Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer 24 Nov 2009 06:52 GMT
... currently in Phase II development in pancreatic cancer. CP-4126 is a novel, patented, lipid-conjugated form ... to be critical for gemcitabine entry into tumor cells, whereas CP-4126 enters and kills tumour ... Boulder, Colorado, and has additional offices in San Francisco, CA and London, UK. About Clavis Pharma ...
- Stopping Tissue Stiffening Is Key To Preventing Aggressive Cancers 20 Nov 2009 14:31 GMT
... lysyl oxidase (LOX) reduced the chance a tumour would form, and also meant tumours that ... target," study co-author from The Institute of Cancer Research in the UK says. "The enzyme ... Valerie Weaver from the University of California, San Francisco, says. "I'm cautiously optimistic. We still have ...
- OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI 17 Nov 2009 17:52 GMT
... Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference Combination of ... Fewer Patient Deaths in Treatment Arm SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- ... data showing that ZYBRESTAT is an active antitumor agent, and we are encouraged by the ...
- OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer a 17 Nov 2009 17:52 GMT
... Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference OXiGENE Reports ... Fewer Patient Deaths in Treatment Arm SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- ... data showing that ZYBRESTAT is an active antitumor agent, and we are encouraged by the ...
- Blocking Tissue Stiffening Enzyme Could Be Key To Preventing Aggressive Cancers 20 Nov 2009 17:11 GMT
... enzymes could be new targets for effective anti-cancer drug therapies. The study was the work ... is also important for progression of the tumor itself. They found that blocking the enzyme ... Valerie Weaver from the University of California, San Francisco, said that the study might also clarify ...
- OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference 17 Nov 2009 17:50 GMT
... SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- ... biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim ... data showing that ZYBRESTAT is an active antitumor agent, and we are encouraged by the ...
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia 18 Nov 2009 21:36 GMT
... the FDA for Rituxan for Chronic Lymphocytic Leukemia SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. - (BUSINESS WIRE) ... people with CLL. According to the American Cancer Society, CLL is the most common adult ...
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 17 Nov 2009 18:10 GMT
... Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial ... and Cancer Therapeutics" International Conference - SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, ... the safety and efficacy (assessed by objective tumor response, PFS and overall survival) of intravenous ...
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer a 17 Nov 2009 18:30 GMT
... SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, ... of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, ... the safety and efficacy (assessed by objective tumor response, PFS and overall survival) of intravenous ...
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 17 Nov 2009 18:35 GMT
... SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, ... of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, ... the safety and efficacy (assessed by objective tumor response, PFS and overall survival) of intravenous ...
- Tissue tension regulates tumor progression 24 Nov 2009 00:44 GMT
... the rigidity of a tissue can induce cancer. The research team identified an enzyme that ... decreased stiffness and reduced the chance a tumor would form. It also caused tumors that ... of Surgery at the University of California, San Francisco. “Our study shows how stiffening of the ...
- Enzyme that plays an important role in the formation of breast tumours identified 25 Nov 2009 06:18 GMT
... - in the cells surrounding the growing tumour. LOX was already known to be involved in the spread of cancer, but the latest study - which appears ... Valerie Weaver, from the University of California, San Francisco, noted: "This study may also help explain ...
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia 18 Nov 2009 21:53 GMT
... the FDA for Rituxan for Chronic Lymphocytic Leukemia Genentech, Inc., a wholly-owned member of the ... people with CLL. According to the American Cancer Society, CLL is the most common adult ... the Roche Group, has headquarters in South San Francisco, Calif. For additional information about the company, ...
- Non-Small Cell Lung Cancer: New non-small cell lung cancer findings from Genentech, Inc. described 19 Nov 2009 05:35 GMT
... in a subset of non-small cell lung cancers (NSCLC). We used profiling of array to ... detection of EML4-ALK fusion in breast and carcinomas in addition to NSCLC. Screening of a ... of Molecular Biology, 1 Way, MS 413A, San Francisco, CA 94080, USA. is: American Association Cancer ...
Powered by 
California Health News Sections
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
reuters.com:
ap.org:
msnbc.msn.com:
healthday.com:
bbc.co.uk: